Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of adjunctive brivaracetam for uncontrolled focal epilepsy
ChiCTR2400092964Phase 3Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brivaracetam in Focal Onset Epilepsy (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Percentage reduction in focal seizure frequency per 28 days during the double-blind treatment period compared with placebo. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
brivaracetam
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on ChiCTR2400092964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092964.